EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future

Mariko Asaoka iD, Shipra Gandhi, Takashi Ishikawa, Kazuaki Takabe iD

Breast Cancer: Basic and Clinical Research · 2020-01 · 14

DOI: 10.1177/1178223420980377 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Breast Cancer: Basic and Clinical Research, online erschienen am 16.12.2020. Verfasst von Mariko Asaoka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Die Arbeit wurde bisher 121-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neoadjuvant chemotherapy (NAC) had been developed as a systematic approach before definitive surgery for the treatment of locally advanced or inoperable breast cancer such as inflammatory breast cancer in the past. In addition to its impact on surgery, the neoadjuvant setting has a benefit of providing the opportunity to monitor the individual drug response. Currently, the subject of NAC has expanded to include patients with early-stage, operable breast cancer because it is revealed that the achievement of a pathologic complete response (pCR) is associated with excellent long-term outcomes, especially in patients with aggressive phenotype breast cancer. In addition, this approach provides the unique opportunity to escalate adjuvant therapy in those with residual disease after NAC. Neoadjuvant chemotherapy in breast cancer is a rapidly evolving topic with tremendous interest in ongoing clinical trials. Here, we review the improvements and further challenges in the NAC setting in translational breast cancer research.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerbiomarkermolecular biologyneoadjuvant chemotherapy

Autor:innen und Institutionen

  • Breast Surgery, Department of Surgical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Breast Oncology and Surgery, Tokyo Medical University Hospital, Tokyo, Japan.
  • Breast Medicine, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Surgery, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA.

ORCID-Profile: Mariko Asaoka, Kazuaki Takabe

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS

Zitieren

APA

Asaoka, M., Gandhi, S., Ishikawa, T., & Takabe, K. (2020). Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer: Basic and Clinical Research, 14. https://doi.org/10.1177/1178223420980377

Vancouver

Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer: Basic and Clinical Research. 2020;14. doi:10.1177/1178223420980377

BibTeX
@article{Asaoka2020,
  author = {Asaoka, Mariko and Gandhi, Shipra and Ishikawa, Takashi and Takabe, Kazuaki},
  title = {Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future},
  journal = {Breast Cancer: Basic and Clinical Research},
  year = {2020},
  volume = {14},
  doi = {10.1177/1178223420980377}
}
Kostenlos starten →